---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-219500"
form_type: "8-K"
ticker: "ANAB"
cik: "0001370053"
company_name: "ANAPTYSBIO, INC"
filed_at: "2026-05-12T20:17:24+00:00"
generated_at: "2026-05-12T20:39:36.099678+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# AnaptysBio Q1 net loss $52.9M; completes First Tracks spin-off, Jemperli royalties up 44%

## Summary
- Net loss per share $1.84 vs $1.28 YoY; collaboration revenue $25.6M (Jemperli royalties $24.7M, +44%).
- Cash $286.5M at March 31; stock repurchase plan of $100M authorized through Dec 31, 2026.
- Spin-off of First Tracks Bio completed Apr 20; now exclusively manages Jemperli (GSK) and imsidolimab (Vanda) financial collaborations.
- Expects >$390M annualized Jemperli royalties by 2029 at GSK's >$2.7B peak sales; Sagard debt paydown by Q2 2027.
- FDA PDUFA Dec 12, 2026 for imsidolimab in GPP; Chris Murphy appointed CFO, Susannah Gray and Owen Hughes to board.

## SEC filing metadata
- accession: 0001193125-26-219500
- form_type: 8-K
- ticker: ANAB
- cik: 0001370053
- company_name: ANAPTYSBIO, INC
- filed_at: 2026-05-12T20:17:24+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1370053/000119312526219500/0001193125-26-219500-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1370053/000119312526219500/anab-20260512.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-219500
- JSON: https://secwatch.observer/filing/0001193125-26-219500.json
- Plain text: https://secwatch.observer/filing/0001193125-26-219500.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.